natgillin/translations-raw huggingface dataset:
Treatment of postmenopausal osteoporosis:
Mehanizam djelovanja Stroncijev ranelat in vitro:
s r.o.
PROTELOS-om.
Symptoms
Mučnina
Children and adolescents Hirobriz Breezhaler should not be given to children or adolescents below the age of 18 years.
Djeca i adolescenti Hirobriz Breezhaler se ne smije davati djeci ili adolescentima mlađim od 18 godina.
Hirobriz Breezhaler should only be used during pregnancy if the expected benefits outweigh the potential risks.
Hirobriz Breezhaler se može koristiti tijekom trudnoće samo ako je očekivana korist veća od mogućih rizika.
Hirobriz Breezhaler should be administered at the same time of the day each day.
Hirobriz Breezhaler treba primjenjivati svakog dana u isto vrijeme.
Do not use Hirobriz Breezhaler - if you are allergic to indacaterol or any of the other ingredients of this medicine (listed in section 6).
Nemojte primjenjivati Hirobriz Breezhaler - ako ste alergični na indakaterol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
In particular, please tell your doctor if you are using: medicines for breathing problems that are similar to Hirobriz Breezhaler (i.e. medicines such as salmeterol and formoterol).
Posebno Vas molimo da obavijestite svog liječnika ako uzimate: lijekove za probleme s disanjem koji su slični Hirobriz Breezhaleru (tj. lijekovi kao što su salmeterol i formoterol).
If signs suggesting allergic reactions (in particular, difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria, skin rash) occur, Hirobriz Breezhaler should be discontinued immediately and alternative therapy instituted.
Ako znakovi koji se pojave ukazuju na alergijsku reakciju (osobito poteškoće u disanju ili gutanju, oticanje jezika, usana i lica, urtikarija, osip na koži), primjenu Hirobriz Breezhaler treba odmah prekinuti i uvesti alternativnu terapiju.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Hirobriz Breezhaler therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje/suzdržati se od liječenja lijekom Hirobriz Breezhaler uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
COPD is a long-term disease and you should use Hirobriz Breezhaler every day and not only when you have breathing problems or other symptoms of COPD.
KOPB je dugotrajna bolest i trebate primijeniti Hirobriz Breezhaler svaki dan, a ne samo kada imate poteškoće s disanjem ili druge simptome KOPB-a.
Please read the following instructions carefully to learn how to use and care for your Hirobriz Breezhaler inhaler.
Molimo Vas da pažljivo pročitate upute u nastavku kako biste naučili primjenjivati i brinuti se o svom Hirobriz Breezhaler inhalatoru.
You should not use Hirobriz Breezhaler unless your doctor tells you so.
Nemojte koristiti Hirobriz Breezhaler osim ako Vam to nije rekao liječnik.
During treatment with Hirobriz Breezhaler, Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine.
Tijekom liječenja Hirobriz Breezhalerom, prestanite primjenjivati lijeka i odmah se obratite svom liječniku ako osjetite stezanje grudnog koša, kašljanje, piskanje ili kratkoću daha odmah nakon primjene lijeka.
The 24-hour bronchodilator effect of Hirobriz Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (tachyphylaxis).
Bronhodilatacijski 24-satni učinak Hirobriz Breezhalera bio je zadržan od prve doze kroz jednogodišnje razdoblje liječenja bez dokaza gubitka djelotvornosti (tahifilaksija).
The mean of the maximum changes in blood glucose were similar between Hirobriz Breezhaler and placebo.
Srednja vrijednost najvećih promjena glukoze u krvi bila je slična za Hirobriz Breezhaler i placebo.
During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Hirobriz Breezhaler at the recommended doses than on placebo.
Tijekom ispitivanja, klinički značajne promjene glukoze u krvi u pravilu su bile češće za 1-2% pri primjeni Hirobriz Breezhalera u preporučenim dozama nego pri primjeni placeba.
As demonstrated in 605 patients with COPD in a 26-week, double-blind, placebo-controlled Phase III study, there was no clinically relevant difference in the development of arrhythmic events monitored over 24 hours, at baseline and up to 3 times during the 26-week treatment period, between patients receiving recommended doses of Hirobriz Breezhaler treatment and those patients who received placebo or treatment with tiotropium.
Kao što je pokazano u 605 bolesnika s KOPB-om u dvostruko slijepom, placebo kontroliranom ispitivanju faze III u trajanju od 26 tjedana, nije bilo klinički značajne razlike u razvoju aritmičkih događaja praćenih tijekom 24 sata, na početku i do 3 puta tijekom razdoblja liječenja od 26 tjedana, između bolesnika koji bili liječeni preporučenim dozama Hirobriz Breezhalera i onih koji su primali placebo ili bili liječeni tiotropijem.
If you have questions about how long to continue your treatment with Hirobriz Breezhaler, talk to your doctor or pharmacist.
Ako imate pitanja o tome koliko dugo trebate provoditi liječenje Hirobriz Breezhalerom, obratite se svom liječniku ili ljekarniku.
As with other inhalation therapy, administration of Hirobriz Breezhaler may result in paradoxical bronchospasm that may be life-threatening.
Kao i kod drugih inhalacijskih terapija, primjena Hirobriz Breezhalera može dovesti do paradoksalnog bronhospazma koji može ugroziti život.
Therefore, long-acting beta2-adrenergic agonists such as Hirobriz Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval.
Stoga, dugodjelujuće beta2adrenergičke agoniste kao što je Hirobriz Breezhaler treba oprezno koristiti u bolesnika s poznatim ili suspektnim produljenjem QT intervala ili u onih koji se liječe lijekom koji utječe na QT interval.
At 600 microgram once-daily, the safety profile of Hirobriz Breezhaler was overall similar to that of recommended doses.
Pri dozi od 600 mikrograma jedanput na dan, sigurnosni profil Hirobriz Breezhalera u cjelini je bio sličan onom pri preporučenim dozama.
The capsules must be administered only using the Hirobriz Breezhaler inhaler (see section 6.6).
Kapsule se moraju primjenjivati samo uz pomoć Hirobriz Breezhaler inhalatora (vidjeti dio 6.6).
If you use more Hirobriz Breezhaler than you should If you have inhaled too much Hirobriz Breezhaler or if someone else uses your capsules, tell your doctor immediately or go to the nearest emergency unit.
Ako ste udahnuli previše Hirobriz Breezhalera ili ako je netko drugi koristio Vaše kapsule, morate odmah obavijestiti svog liječniku ili otići u najbližu jedinicu hitne pomoći.
Concomitant administration of other sympathomimetic medicinal products (alone or as part of combination therapy) may potentiate adverse reactions to Hirobriz Breezhaler.
Istodobna primjena drugih simpatomimetičkih lijekova (samih ili u kombiniranom liječenju) može potencirati nuspojave Hirobriz Breezhalera.
Hirobriz Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo.
Dokazano je da Hirobriz Breezhaler smanjuje plućnu hiperinflaciju, što dovodi do povećanog kapaciteta udisanja tijekom vježbe i u mirovanju, u usporedbi s placebom.
Hirobriz Breezhaler should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists.
Hirobriz Breezhaler ne treba koristiti zajedno s drugim dugodjelujućim beta2-adrenergičkim agonistima ili lijekovima koji sadrže dugodjelujuće beta2-adrenergičke agoniste.
In addition, patients treated with Hirobriz Breezhaler required significantly less rescue medication, had more days when no rescue medication was needed compared to placebo and had a significantly improved percentage of days with no daytime symptoms.
Osim toga, bolesnici liječeni Hirobriz Breezhalerom trebali su značajno manje lijekova za hitno ublažavanje simptoma, imali su više dana bez lijekova za hitno ublažavanje simptoma u usporedbi s placebom te su imali značajno povećanje postotka dana bez dnevnih simptoma.
Systemic exposures (AUC) in rats and mice at the no-observed adverse effect levels in these studies were at least 7- and 49-fold higher, respectively, than in humans treated with Hirobriz Breezhaler once a day at a dose of 300 microgram.
Sistemska izloženost (AUC) na razinama na kojima nisu bile zapažene nuspojave u ovim je ispitivanjima u štakora i miševa bila najmanje 7, odnosno 49 puta veća od one u ljudi liječenih Hirobriz Breezhalerom jedanput na dan u dozi od 300 mikrograma.
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Hirobriz Breezhaler at recommended therapeutic doses (see section 5.1).
Klinički važni učinci produljenja QTc-intervala nisu bili zapaženi u ispitivanjima Hirobriz Breezhalera u preporučenim terapijskim dozama (vidjeti dio 5.1).
The European Medicines Agency has waived the obligation to submit the results of studies with Hirobriz Breezhaler in all subsets of the paediatric population in chronic obstructive pulmonary disease (COPD) (see section 4.2 for information on paediatric use).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Hirobriz Breezhalera u svim podskupinama pedijatrijske populacije s kroničnom opstruktivnom plućnom bolešću (KOPB) (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Hirobriz Breezhaler is a long-acting beta2-adrenergic agonist, which is only indicated for COPD and should not be used in asthma due to the absence of long-term outcome data in asthma.
Hirobriz Breezhaler je dugodjelujući beta2-adrenergički agonist koji je indiciran samo za KOPB i ne treba se koristiti u astmi jer nema podataka o ishodima pri dugotrajnoj primjeni u astmi.
Paediatric population There is no relevant use of Hirobriz Breezhaler in the paediatric population (under 18 years).
Nema relevantne primjene Hirobriz Breezhaler u pedijatrijskoj populaciji (mlađih od 18 godina).
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Hirobriz Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2adrenergic agonists.
Iako nije bio zapažen klinički značajan učinak na kardiovaskularni sustav nakon primjene Hirobriz Breezhalera u preporučenim dozama, indakaterol treba, kao i druge beta2-adrenergičke agoniste, oprezno primjenjivati u bolesnika s kardiovaskularnim poremećajima (koronarna srčana bolest, akutni infarkt miokarda, srčane aritmije, hipertenzija), u bolesnika s konvulzivnim poremećajima ili tireotoksikozom te u bolesnika koji imaju neuobičajeni odgovor na beta2-adrenergičke agoniste.
Hirobriz Breezhaler has no or negligible influence on the ability to drive and use machines.
Hirobriz Breezhaler ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
If paradoxical bronchospasm occurs Hirobriz Breezhaler should be discontinued immediately and alternative therapy substituted.
Ako dođe do pojave paradoksalnog bronhospazma, primjenu Hirobriz Breezhalera treba odmah prekinuti i zamijeniti ga drugim lijekom.
Hirobriz Breezhaler, administered once a day at doses of 150 and 300 microgram consistently provided clinically significant improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours across a number of clinical pharmacodynamic and efficacy studies.
Hirobriz Breezhaler primijenjen jedanput na dan u dozi od 150 i 300 mikrograma dosljedno je pružao klinički značajna poboljšanja plućne funkcije (mjereno forsiranim izdisajnim volumenom u jednoj sekundi, FEV1) tijekom 24 sata kroz brojna farmakodinamička ispitivanja i ispitivanja djelotvornosti.
How long to continue your treatment with Hirobriz Breezhaler Keep using your treatment with Hirobriz Breezhaler for as long as your doctor tells you.
Koliko dugo trebate nastaviti svoje liječenje Hirobriz Breezhalerom Nastavite svoje liječenje Hirobriz Breezhalerom toliko dugo koliko Vam je rekao liječnik.
Hirobriz Breezhaler capsules must always be stored in the blister, and only removed immediately before use.
Hirobriz Breezhaler kapsule se moraju uvijek čuvati u blisteru te se smiju izvaditi tek neposredno prije primjene.
At the recommended doses, the adverse reaction profile of Hirobriz Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation.
U preporučenim dozama profil nuspojava Hirobriz Breezhalera u bolesnika s KOPB-om pokazuje klinički beznačajne sistemske učinke beta2-adrenergičke stimulacije.
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Hirobriz Breezhaler.
Iako indakaterol nije u pravilu utjecao na reproduktivne parametre u ispitivanju plodnosti u štakora, zapažen je pad broja trudnih F1 potomaka u ispitivanju peri- i post-razvoja u štakora pri izloženosti 14 puta većoj od one u ljudi liječenih Hirobriz Breezhalerom.
What Hirobriz Breezhaler is and what it is used for What you need to know before you use Hirobriz Breezhaler How to use Hirobriz Breezhaler Possible side effects
Što je Hirobriz Breezhaler i za što se koristi Što morate znati prije nego počnete primjenjivati Hirobriz Breezhaler Kako primjenjivati Hirobriz Breezhaler Moguće nuspojave
Hirobriz Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators.
Hirobriz Breezhaler sadrži djelatnu tvar indakaterol koja pripada skupini lijekova koji se nazivaju bronhodilatatori.
Your Hirobriz Breezhaler pack: Each Hirobriz Breezhaler pack contains: one Hirobriz Breezhaler inhaler one or more blister containing Hirobriz Breezhaler capsules to be used in the inhaler.
Vaše Hirobriz Breezhaler pakiranje: Jedno Hirobriz Breezhaler pakiranje sadrži: jedan Hirobriz Breezhaler inhalator jedan ili više blistera koji sadrže Hirobriz Breezhaler kapsule koje se koriste u inhalatoru.
The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Hirobriz Breezhaler inhaler.
Preporučena doza je udisanje sadržaja jedne kapsule od 150 mikrograma jedanput na dan uz pomoć Hirobriz Breezhaler inhalatora.
Hirobriz Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function.
Hirobriz Breezhaler primijenjen jedanput na dan u dozama od 150 mikrograma i 300 mikrograma pokazao je klinički značajna poboljšanja plućne funkcije.
Immediate hypersensitivity reactions have been reported after administration of Hirobriz Breezhaler.
Reakcije preosjetljivosti su odmah bile prijavljene nakon primjene Hirobriz Breezhalera.
Hirobriz Breezhaler has not been investigated in patients with not well controlled diabetes mellitus.
Hirobriz Breezhaler se nije ispitivao u bolesnika s loše kontroliranom šećernom bolešću.
The inhalation of the content of one 300 microgram capsule once a day, using the Hirobriz Breezhaler inhaler has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD.
Dokazano je da udisanje sadržaja kapsule od 300 mikrograma jedanput na dan uz pomoć Hirobriz Breezhaler inhalatora omogućava dodatnu kliničku korist s obzirom na dispneju, osobito u bolesnika s teškim KOPB-om.
Hirobriz Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD).
Hirobriz Breezhaler se koristi da bi se olakšalo disanje u odraslih bolesnika koji imaju poteškoće s disanjem zbog plućne bolesti koja se zove kronična opstruktivna plućna bolest (KOPB).
What you need to know before you use Hirobriz Breezhaler
Što morate znati prije nego počnete primjenjivati Hirobriz Breezhaler
Breezhaler capsules with any other inhaler, and do not use Hirobriz Breezhaler inhaler to take any other capsule medicine.
Hirobriz Breezhaler kapsule s nekim drugim inhalatorom i ne koristite Hirobriz Breezhaler inhalator za primjenu bilo kojeg drugog lijeka u kapsulama.
Only use the capsules with the inhaler provided in this pack (Hirobriz Breezhaler inhaler).
Koristite samo kapsule koje ste dobili uz inhalator u ovom pakiranju (Hirobriz Breezhaler inhalator).
Hirobriz Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Hirobriz Breezhaler nije indiciran za liječenje akutnih epizoda bronhospazma, tj. kao lijek za hitna stanja.
There are no data available for use of Hirobriz Breezhaler in patients with severe hepatic impairment.
Nema podataka o primjeni Hirobriz Breezhalera u bolesnika s teškim oštećenjem jetre.
The Hirobriz Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
Program ispitivanja faze III tijekom razvoja Hirobriz Breezhalera uključivao je bolesnike s kliničkom dijagnozom umjerenog do teškog KOPB-a.
Show the pack of Hirobriz Breezhaler.
Pokažite pakiranje Hirobriz Breezhalera.
Hirobriz Breezhaler contains lactose
Hirobriz Breezhaler sadrži laktozu
In the event of deterioration of COPD during treatment with Hirobriz Breezhaler, a reevaluation of the patient and of the COPD treatment regimen should be undertaken.
Ako dođe do pogoršanja KOPB-a tijekom liječenja Hirobriz Breezhalerom, bolesnika treba ponovno pregledati i provesti liječenje KOPB-a.
What Hirobriz Breezhaler contains - Each Hirobriz Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate.
Što Hirobriz Breezhaler sadrži - Svaka Hirobriz Breezhaler 150 mikrogramska kapsula sadrži 150 mikrograma indakaterola u obliku indakaterolmaleata.
Talk to your doctor or pharmacist before using Hirobriz Breezhaler if you have asthma (in this case you should not use Hirobriz Breezhaler).
Obratite se svom liječniku ili ljekarniku prije nego primijenite Hirobriz Breezhaler ako imate astmu (u tom slučaju ne biste trebali koristiti Hirobriz Breezhaler). ako imate problema sa srcem. ako imate epilepsiju. ako imate problema sa štitnjačom (tireotoksikoza). ako imate šećernu bolest.
The Hirobriz Breezhaler inhaler provided with each new prescription should be used.
Potrebno je koristiti Hirobriz Breezhaler inhalator koji se dobije sa svakim novim receptom.
Hirobriz Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar.
Hirobriz Breezhaler 150 mikrograma kapsule imaju crnu oznaku „IDL 150“ otisnutu iznad crne crte i crni logo proizvođača ( ) otisnut ispod crne crte.
Other medicines and Hirobriz Breezhaler
Drugi lijekovi i Hirobriz Breezhaler
Always keep the Hirobriz Breezhaler inhaler and capsules in a dry place.
Uvijek držite Hirobriz Breezhaler inhalator i kapsule na suhom mjestu.
If you forget to inhale a dose, inhale just one dose at the usual time the next day.
Ako ste zaboravili primijeniti Hirobriz Breezhaler Ako ste zaboravili udahnuti svoju dozu, udahnite samo jednu dozu u uobičajeno vrijeme sljedećeg dana.
What Hirobriz Breezhaler is and what it is used for
Što je Hirobriz Breezhaler i za što se koristi
Hirobriz Breezhaler is a single-dose inhalation device.
Hirobriz Breezhaler je jednodozni inhalator.
An increase in the daily dose of Hirobriz Breezhaler beyond the maximum dose of 300 microgram is not appropriate.
Povećanje dnevne doze iznad doze od 300 mikrograma nije primjereno.
Hirobriz Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar.
Hirobriz Breezhaler 300 mikrograma kapsule imaju plavu oznaku „IDL 300“ otisnutu iznad plave crte i plavi logo proizvođača ( ) otisnut ispod plave crte.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in a capsule.
Hirobriz Breezhaler inhalator Vam omogućava udisati lijek koji se nalazi u kapsuli.
Upon initiation of treatment with Hirobriz Breezhaler plasma glucose should be monitored more closely in diabetic patients.
Nakon početka liječenja Hirobriz Breezhalerom, u bolesnika sa šećernom bolešću treba pomno pratiti glukozu u plazmi.
Carton containing 30 capsules and one Hirobriz Breezhaler inhaler.
Kutija sadrži 30 kapsula i jedan Hirobriz Breezhaler inhalator.
Hirobriz Breezhaler capsules must not be swallowed.
Hirobriz Breezhaler kapsule se ne smiju progutati.
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Hirobriz Breezhaler je indiciran za terapiju održavanja bronhodilatacije kod opstrukcije dišnih puteva u odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB).
Carton containing 10 capsules and one Hirobriz Breezhaler inhaler.
Kutija sadrži 10 kapsula i jedan Hirobriz Breezhaler inhalator.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in an Hirobriz Breezhaler capsule.
Hirobriz Breezhaler inhalator Vam omogućuje udisanje lijeka koji se nalazi u Hirobriz Breezhaler kapsuli.
When you start a new pack, use the new Hirobriz Breezhaler inhaler that is supplied in the pack.
Kada otvorite novo pakiranje, upotrijebite novi Hirobriz Breezhaler inhalator koji je priložen u pakiranju.
Driving and using machines It is unlikely that Hirobriz Breezhaler will affect your ability to drive and use machines.
Nije vjerojatno da će Hirobriz Breezhaler utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
- Each Hirobriz Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate.
- Svaka Hirobriz Breezhaler 300 mikrogramska kapsula sadrži 300 mikrograma indakaterola u obliku indakaterolmaleata.
INSTRUCTIONS FOR USE OF HIROBRIZ BREEZHALER INHALER
UPUTE ZA PRIMJENU HIROBRIZ BREEZHALER INHALATORA
Hirobriz Breezhaler inhaler
Hirobriz Breezhaler inhalator
Always use the new Hirobriz Breezhaler inhaler that comes with your new pack.
Uvijek koristite Hirobriz Breezhaler inhalator koji se nalazi u Vašem novom pakiranju.
Never place a Hirobriz Breezhaler capsule directly into the mouthpiece of the Hirobriz Breezhaler inhaler.
Nikada ne stavljajte Hirobriz Breezhaler kapsulu direktno u nastavak za usta Hirobriz Breezhaler inhalatora.
Only use the Hirobriz Breezhaler inhaler contained in this pack.
Koristite samo Hirobriz Breezhaler inhalator koji se nalazi u ovom pakiranju.
• Only use the Hirobriz Breezhaler inhaler contained in this pack.
• Koristite samo Hirobriz Breezhaler inhalator koji se nalazi u ovom pakiranju.
• When you start a new pack, only use the new Hirobriz Breezhaler inhaler that is supplied in the pack.
• Kada otvorite novo pakiranje, koristite samo novi Hirobriz Breezhaler inhalator koji se nalazi u ovom pakiranju.
The magnitude of exposure increases due to interactions does not raise any safety concerns given the safety experience of treatment with Hirobriz Breezhaler in clinical studies of up to one year at doses up to twice the maximum recommended therapeutic dose.
Iskustvo iz ispitivanja vezanih uz sigurnost liječenja Hirobriz Breezhalerom u trajanju do jedne godine u dozama dvostruko većim od najveće preporučene terapijske doze pokazuje da se s porastom izloženosti zbog interakcija ne smanjuje sigurnost primjene lijeka.
How much Hirobriz Breezhaler to use
Koliko Hirobriz Breezhalera primijeniti
Never take the Hirobriz Breezhaler inhaler apart.
Nikad nemojte rastavljati Hirobriz Breezhaler inhalator.